Prognostic Values of Various Clinical Factors and GeneticSubtypes for Diffuse Large B-cell lymphoma Patients: ARetrospective Analysis of 227 Cases

Abstract

Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-celllymphoma (DLBCL) patients. <br/><b>Methods</b>: Two hundred and twenty-seven DLBCL patients were retrospectivelyreviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)regimen or rituximab plus the CHOP (RCHOP) regimen. <br/><b>Results</b>: Lactate dehydrogenase (LDH), β2-microglobulin (β2-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predictingthe prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-celllike(GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOPmanagement, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%,P=0.288). <br/><b>Conclusion</b>: Elevated LDH and β2-M levels, positive B symptoms, Ann Arbor stage III/IV, and primarynodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have abetter prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment withthe addition of rituximab can improve the prognosis of patients with DLBCL.